Pharma Mar (PHM) Stock Overview
A biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, China, Germany, Ireland, France, rest of the European Union, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
PHM Community Fair Values
Create NarrativeSee what 47 others think this stock is worth. Follow their fair value or set your own to get alerts.
Pharma Mar, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €71.90 |
| 52 Week High | €105.80 |
| 52 Week Low | €65.00 |
| Beta | 0.25 |
| 1 Month Change | -18.25% |
| 3 Month Change | -9.10% |
| 1 Year Change | -5.15% |
| 3 Year Change | 12.13% |
| 5 Year Change | -28.81% |
| Change since IPO | 51.69% |
Recent News & Updates
There May Be Underlying Issues With The Quality Of Pharma Mar's (BME:PHM) Earnings
Nov 07
Pharma Mar, S.A. (BME:PHM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Nov 02Is Pharma Mar (BME:PHM) A Risky Investment?
Oct 29Recent updates
There May Be Underlying Issues With The Quality Of Pharma Mar's (BME:PHM) Earnings
Nov 07Pharma Mar, S.A. (BME:PHM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Nov 02Is Pharma Mar (BME:PHM) A Risky Investment?
Oct 29Risks To Shareholder Returns Are Elevated At These Prices For Pharma Mar, S.A. (BME:PHM)
Aug 03Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.80
Jun 16Pharma Mar (BME:PHM) Has Announced That It Will Be Increasing Its Dividend To €0.80
May 23
ZEPZELCA's EMA Submission Will Broaden Cancer Treatment Availability In Europe
Successful approval of ZEPZELCA in Europe and new markets could significantly boost PharmaMar’s future revenues, leveraging positive trial results.We Think Shareholders Should Be Aware Of Some Factors Beyond Pharma Mar's (BME:PHM) Profit
Mar 06There's Reason For Concern Over Pharma Mar, S.A.'s (BME:PHM) Massive 27% Price Jump
Feb 13Pharma Mar, S.A.'s (BME:PHM) Price Is Right But Growth Is Lacking After Shares Rocket 55%
Oct 16Pharma Mar, S.A.'s (BME:PHM) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Jul 28Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65
Jun 01Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry
May 28Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 03Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden
Jan 25Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate
Apr 28We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability
Mar 08Analyst Forecasts Just Became More Bearish On Pharma Mar, S.A. (BME:PHM)
Mar 05Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet
Feb 09We Think Pharma Mar (BME:PHM) Can Manage Its Debt With Ease
Oct 27An Intrinsic Calculation For Pharma Mar, S.A. (BME:PHM) Suggests It's 21% Undervalued
Sep 27Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?
Jul 15Growth Investors: Industry Analysts Just Upgraded Their Pharma Mar, S.A. (BME:PHM) Revenue Forecasts By 24%
May 04Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet
Apr 11There Is A Reason Pharma Mar, S.A.'s (BME:PHM) Price Is Undemanding
Mar 16Shareholder Returns
| PHM | ES Biotechs | ES Market | |
|---|---|---|---|
| 7D | -3.2% | -0.05% | 0.3% |
| 1Y | -5.1% | 9.4% | 31.2% |
Return vs Industry: PHM underperformed the Spanish Biotechs industry which returned 9.5% over the past year.
Return vs Market: PHM underperformed the Spanish Market which returned 31.9% over the past year.
Price Volatility
| PHM volatility | |
|---|---|
| PHM Average Weekly Movement | 5.2% |
| Biotechs Industry Average Movement | 7.2% |
| Market Average Movement | 3.0% |
| 10% most volatile stocks in ES Market | 6.4% |
| 10% least volatile stocks in ES Market | 0.6% |
Stable Share Price: PHM's share price has been volatile over the past 3 months compared to the Spanish market.
Volatility Over Time: PHM's weekly volatility (5%) has been stable over the past year, but is still higher than 75% of Spanish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 500 | Jose Fernandez Sousa-Faro | www.pharmamar.com |
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, China, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata for the treatment of soft tissue sarcoma and recurrent ovarian cancer; Aplidin that is extracted from the ascidian Aplidium albicans for the treatment of relapsed multiple myeloma; and Zepzelca, a synthetic compound derived from a colonial ascidian to treat patients with metastatic small cell lung cancer, as well as in Phase IIb/III trials for the treatment of metastatic leiomyosarcoma.
Pharma Mar, S.A. Fundamentals Summary
| PHM fundamental statistics | |
|---|---|
| Market cap | €1.24b |
| Earnings (TTM) | €34.01m |
| Revenue (TTM) | €179.28m |
Is PHM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHM income statement (TTM) | |
|---|---|
| Revenue | €179.28m |
| Cost of Revenue | €9.80m |
| Gross Profit | €169.48m |
| Other Expenses | €135.47m |
| Earnings | €34.01m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.98 |
| Gross Margin | 94.53% |
| Net Profit Margin | 18.97% |
| Debt/Equity Ratio | 24.1% |
How did PHM perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/06 11:30 |
| End of Day Share Price | 2025/11/06 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pharma Mar, S.A. is covered by 11 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Guilherme Sampaio | Banco BPI, S.A. |
| Patricia Cifuentes | Bestinver Sociedad De Valores, S.A |
| Keay Nakae | Chardan Capital Markets, LLC |